EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients

Moritz Platzer, David Totschnig, Mario Karolyi, Tamara Clodi-Seitz, Christoph Wenisch, Alexander Zoufaly

Wiener klinische Wochenschrift · 2024

DOI: 10.1007/s00508-024-02377-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiener klinische Wochenschrift, 2024. Verfasst von Moritz Platzer und 5 weiteren Autor:innen. Beteiligte Einrichtung: 4. Med. Department for Infectious Diseases and Tropical Medicine, Klinik Favoriten, Wiener Gesundheitsverbund, Vienna, Austria. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Disease Progression, COVID-19 Drug Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Austria, Sigmund Freud Privatuniversität Wien.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiviral drugs have become crucial in managing COVID-19, reducing complications and mortality. Remdesivir has emerged as an effective therapeutic drug for hospitalized patients at risk of disease progression, especially when alternative treatments are infeasible. While the recommended treatment duration of remdesivir extends up to 7 days post-symptom onset, this study examines how early remdesivir administration impacts clinical outcomes.

Methods

We conducted a retrospective analysis using clinical data from consecutively PCR confirmed SARS-CoV‑2 adult patients (≥ 18 years) who received remdesivir during their hospitalization at the department of infectious diseases, Klinik Favoriten in Vienna. The data covered the period from July 1, 2021, to April 31, 2022. Patients were divided into two groups based on the timing of remdesivir administration: an early group (0–3 days since symptom onset) and a late group (≥ 4 days since symptom onset). The primary outcome was in-hospital disease progression, assessed using the WHO COVID-19 Clinical Progression Scale (≥ 1 point increase). Multivariable logistic regression, adjusted for age, sex, SARS-CoV‑2 variant, and COVID-19 vaccination status, was used to assess clinical outcomes.

Results

In total 219 patients were included of whom 148 (67.6%) were in the early group and 71 (32.4%) were in the late group. The average age was 66.5 (SD: 18.0) years, 68.9% of the patients were vaccinated, and 72.6% had the Omicron virus variant. Late remdesivir administration was associated with a significantly higher probability of needing high-flow oxygen therapy (OR 2.52, 95% CI 1.40–4.52, p = 0.002) and ICU admission (OR 4.34, 95% CI 1.38–13.67, p = 0.012) after adjusting for confounders. In the late group there was a trend towards a higher risk of clinical worsening (OR 2.13, 95% CI 0.98–4.64, p = 0.056) and need for any oxygen therapy (OR 1.85, 95% CI 0.94–3.64, p = 0.074).

Conclusion

Compared to patients who received remdesivir within the first 3 days after symptom onset, administering remdesivir after day 3 in hospitalized COVID-19 patients is associated with higher risk for complications, such as the need for high-flow oxygen therapy and ICU admission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAdenosine MonophosphateDisease ProgressionCOVID-19 Drug TreatmentAntiviral AgentsCOVID-19HospitalizationHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeAdultSARS-CoV-2AustriaDrug Administration ScheduleAged, 80 and over

Stichwörter der Autor:innen

COVID-19 (omicron & delta)Disease progressionHospitalized adultsRemdesivirTiming of therapy

Substanzen

AlanineremdesivirAdenosine MonophosphateAntiviral Agents

Autor:innen und Institutionen

  • 4. Med. Department for Infectious Diseases and Tropical Medicine, Klinik Favoriten, Wiener Gesundheitsverbund, Vienna, Austria.
  • 4. Med. Department for Infectious Diseases and Tropical Medicine, Klinik Favoriten, Wiener Gesundheitsverbund, Vienna, Austria. alexander.zoufaly@gesundheitsverbund.at.
  • Faculty of Medicine, Sigmund Freud University, Vienna, Austria. alexander.zoufaly@gesundheitsverbund.at.

Förderung

  • Gilead Sciences Austria
  • Sigmund Freud Privatuniversität Wien

Zitieren

APA

Platzer, M., Totschnig, D., Karolyi, M., Clodi-Seitz, T., Wenisch, C., & Zoufaly, A. (2024). The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-024-02377-7

Vancouver

Platzer M, Totschnig D, Karolyi M, Clodi-Seitz T, Wenisch C, Zoufaly A. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients. Wiener klinische Wochenschrift. 2024. doi:10.1007/s00508-024-02377-7

BibTeX
@article{Platzer2024,
  author = {Platzer, Moritz and Totschnig, David and Karolyi, Mario and Clodi-Seitz, Tamara and Wenisch, Christoph and Zoufaly, Alexander},
  title = {The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients},
  journal = {Wiener klinische Wochenschrift},
  year = {2024},
  doi = {10.1007/s00508-024-02377-7}
}
Kostenlos starten →